Gilead Sciences (GILD) Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Assets came in at $49.4 billion in Q2 2026, down 11.41% on a YoY basis from $55.7 billion in Q2 2025, and down 12.29% quarter-over-quarter from $56.3 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Assets for 18 consecutive years, with $49.4 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets fell 11.41% year-over-year to $49.4 billion; the trailing twelve-month figure through Jun 2026 stood at $49.4 billion (down 11.41% YoY), and the FY2025 full-year result was $59.0 billion, changed 0.05% from the prior year.
- Assets slipped to $49.4 billion in Q2 2026 per GILD's latest filing, from $56.3 billion in the prior quarter.
- Across five years, Assets topped out at $63.2 billion in Q4 2022 and bottomed at $49.4 billion in Q2 2026.
- Historically, Assets has averaged $58.8 billion across 5 years, with a median of $59.0 billion in 2024.
- The sharpest annual moves came in 2024 and 2025: Assets fell 14.05% in 2024, then climbed 7.35% in 2025.
- Over 5 years, Assets stood at $63.2 billion in 2022, then decreased by 1.66% to $62.1 billion in 2023, then fell by 5.04% to $59.0 billion in 2024, then increased by 0.05% to $59.0 billion in 2025, then declined by 16.37% to $49.4 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $49.4 billion, $56.3 billion, and $59.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 2.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.36 Bn |
| Mar 31, 2026 | 56.28 Bn |
| Dec 31, 2025 | 59.02 Bn |
| Sep 30, 2025 | 58.53 Bn |
| Jun 30, 2025 | 55.72 Bn |
| Mar 31, 2025 | 56.43 Bn |
| Dec 31, 2024 | 59.00 Bn |
| Sep 30, 2024 | 54.53 Bn |
| Jun 30, 2024 | 53.58 Bn |
| Mar 31, 2024 | 56.29 Bn |
| Dec 31, 2023 | 62.13 Bn |
| Sep 30, 2023 | 62.37 Bn |
| Jun 30, 2023 | 62.34 Bn |
| Mar 31, 2023 | 61.88 Bn |
| Dec 31, 2022 | 63.17 Bn |
| Sep 30, 2022 | 62.56 Bn |
| Jun 30, 2022 | 62.87 Bn |
| Mar 31, 2022 | 63.08 Bn |
| Dec 31, 2021 | 67.95 Bn |
| Sep 30, 2021 | 67.10 Bn |